Abstract
N6-methyladenosine (m6A) is the most abundant RNA modification. M6A RNA methylation is reversible: m6A is installed by “writers”, removed by “erasers”, and recognized by “readers”. Readers are executors to regulate RNA metabolism by recognizing specific m6A sites, including RNA splicing, export, translation and decay. YTHDF2 is the first identified m6A reader protein. YTHDF2 interacts with m6A-containing transcripts to accelerate the degradation process and regulate various biological processes, such as viral infection, stem cell development and cancer progression. Although there are some reviews about m6A modification in physiological and pathological processes, few reviews focus on roles of YTHDF2 in cancers to date. Therefore, in this review, we attempted to systematically summarize m6A reader protein YTHDF2: its structure, mechanisms in regulating RNA metabolism, roles in cancer progression and potential application for cancer treatment, which might inspire new ideas for m6A research in cancers and provide novel insights into cancer treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Availability of data and materials
The material supporting the conclusion of this review has been included within the article.
Abbreviations
- 3’UTR::
-
3’Untranslated regions
- ALKBH5::
-
α-Ketoglutarate-dependent dioxygenase homolog 5
- AML::
-
Acute myeloid leukemia
- BC::
-
Bladder cancer
- CCND1::
-
Cyclin D1
- CCR4-NOT::
-
Carbon catabolite regression 4-negative on TATA-less
- CDS::
-
Coding region
- CRC::
-
Colorectal cancer
- DAPK3::
-
Death-associated protein kinase-3
- EEC::
-
Endometrioid endometrial cancer
- eIF4G1::
-
Eukaryotic translation initiation factor gamma 1
- EMT::
-
Epithelial–mesenchymal transition
- ESCC::
-
Esophageal squamous cell carcinoma
- FBW7::
-
F-box and WD repeat domain-containing 7
- FTO::
-
Fat mass and obesity-associated protein
- GBM::
-
Glioblastoma
- GC::
-
Gastric cancer
- GSC::
-
Glioblastoma stem cell
- GSK3B::
-
Glycogen synthase kinase-3 beta
- HCC::
-
Hepatocellular carcinoma
- HIF1α::
-
Hypoxia-inducible factor 1α
- HNRNPG::
-
Heterogeneous nuclear ribonucleoprotein G
- HRE::
-
Hypoxia-response element
- HRSP12::
-
Heat-responsive protein 12
- HSCs::
-
Hematopoietic stem cells
- IGF2BPs::
-
Insulin-like growth factor-2 mRNA-binding proteins
- IL11::
-
Interleukin 11
- IRS1::
-
Insulin receptor substrate 1
- KLF4::
-
Kruppel-like factor 4
- LCD::
-
Low complexity domain
- LncRNAs::
-
Long noncoding RNAs
- LSCs::
-
Leukemia stem cells
- LUAD::
-
Lung adenocarcinoma
- m6A::
-
N6-methyladenosine
- METTL3::
-
Methyltransferase-like 3
- MTX::
-
Methyltransferase complex
- ncRNAs::
-
Noncoding RNAs
- NEAT1::
-
Nuclear-enriched abundant transcript 1
- NK cells::
-
Natural killer cells
- NSCLC::
-
Non-small-cell lung cancer
- OSCC::
-
Oral squamous cell carcinoma
- P bodies::
-
MRNA-processing bodies
- PC::
-
Prostate cancer
- PRSS23::
-
Serine protease 23
- PTC::
-
Papillary thyroid carcinoma
- R-2HG::
-
R-2-hydroxyglutarate
- RBD::
-
RNA-binding domain
- RBM15::
-
RNA-binding motif protein 15
- RCC::
-
Renal cell carcinoma
- RFS::
-
Relapse-free survival
- SCF::
-
Skp1-Cullin-F-box
- SERPINE2::
-
Serpin family E member 2
- SETD7::
-
SET domain containing 7
- SH::
-
Superfamily homology
- siRNA::
-
Small interference RNA
- SOX4::
-
SRY-related high-mobility-group box 4
- SSTR2::
-
Somatostatin receptor 2
- TAN::
-
Tumor-associated neutrophil
- TKIs::
-
Tyrosine kinase inhibitors
- TNBC::
-
Triple-negative breast cancer
- TNFRSF1B::
-
Tumor necrosis factor receptor superfamily member 1B
- WTAP::
-
WT1-associated protein
- XIST::
-
X inactivate-specific transcript
- YTH::
-
YT521-B homology
- YTH-YTHDF2::
-
YTH domain of human YTHDF2
- ZC3H13::
-
Zinc finger CCCH-type containing 13
References
Adams JM, Cory S (1975) Modified nucleosides and bizarre 5′-termini in mouse myeloma mRNA. Nature 255(5503):28–33. https://doi.org/10.1038/255028a0
Alarcón CR, Lee H, Goodarzi H, Halberg N, Tavazoie SF (2015) N6-methyladenosine marks primary microRNAs for processing. Nature 519(7544):482–485. https://doi.org/10.1038/nature14281
Al-Harbi S, Aljurf M, Mohty M, Almohareb F, Ahmed SOA (2020) An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1. Blood Adv 4(1):229–238. https://doi.org/10.1182/bloodadvances.2019000168
Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT, Dewald GW, Kantarjian HM, Pierce SR, Estey EH (2006) The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 135(2):165–173. https://doi.org/10.1111/j.1365-2141.2006.06276.x
Badis G, Saveanu C, Fromont-Racine M, Jacquier A (2004) Targeted mRNA degradation by deadenylation-independent decapping. Mol Cell 15(1):5–15. https://doi.org/10.1016/j.molcel.2004.06.028
Beemon K, Keith J (1977) Localization of N6-methyladenosine in the Rous sarcoma virus genome. J Mol Biol 113(1):165–179. https://doi.org/10.1016/0022-2836(77)90047-x
Boccaletto P, Machnicka MA, Purta E, Piatkowski P, Baginski B, Wirecki TK, de Crécy-Lagard V, Ross R, Limbach PA, Kotter A, Helm M, Bujnicki JM (2018) MODOMICS: a database of RNA modification pathways 2017 update. Nucleic Acids Res 46(D1):D303-d307. https://doi.org/10.1093/nar/gkx1030
Carroll SM, Narayan P, Rottman FM (1990) N6-methyladenosine residues in an intron-specific region of prolactin pre-mRNA. Mol Cell Biol 10(9):4456–4465. https://doi.org/10.1128/mcb.10.9.4456-4465.1990
Chai RC, Chang YZ, Chang X, Pang B, An SY, Zhang KN, Chang YH, Jiang T, Wang YZ (2021) YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m(6)A modification to activate NF-κB and promote the malignant progression of glioma. J Hematol Oncol 14(1):109. https://doi.org/10.1186/s13045-021-01124-z
Chen J, Sun Y, Xu X, Wang D, He J, Zhou H, Lu Y, Zeng J, Du F, Gong A, Xu M (2017) YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells. Cell Cycle 16(23):2259–2271. https://doi.org/10.1080/15384101.2017.1380125
Chen Z, Qi M, Shen B, Luo G, Wu Y, Li J, Lu Z, Zheng Z, Dai Q, Wang H (2019a) Transfer RNA demethylase ALKBH3 promotes cancer progression via induction of tRNA-derived small RNAs. Nucleic Acids Res 47(5):2533–2545. https://doi.org/10.1093/nar/gky1250
Chen XY, Zhang J, Zhu JS (2019b) The role of m(6)A RNA methylation in human cancer. Mol Cancer 18(1):103. https://doi.org/10.1186/s12943-019-1033-z
Chen X, Xu M, Xu X, Zeng K, Liu X, Pan B, Li C, Sun L, Qin J, Xu T, He B, Pan Y, Sun H, Wang S (2020) METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer. Mol Cancer 19(1):106. https://doi.org/10.1186/s12943-020-01220-7
Chen Z, Shao YL, Wang LL, Lin J, Zhang JB, Ding Y, Gao BB, Liu DH, Gao XN (2021a) YTHDF2 is a potential target of AML1/ETO-HIF1α loop-mediated cell proliferation in t(8;21) AML. Oncogene 40(22):3786–3798. https://doi.org/10.1038/s41388-021-01818-1
Chen MH, Fu LS, Zhang F, Yang Y, Wu XZ (2021b) LncAY controls BMI1 expression and activates BMI1/Wnt/β-catenin signaling axis in hepatocellular carcinoma. Life Sci 280:119748. https://doi.org/10.1016/j.lfs.2021.119748
Chen Y, Ling Z, Cai X, Xu Y, Lv Z, Man D, Ge J, Yu C, Zhang D, Zhang Y, Xie H, Zhou L, Wu J, Zheng S (2021c) Activation of YAP1 by N6-methyladenosine-modified CircCPSF6 drives malignancy in hepatocellular carcinoma. Cancer Res. https://doi.org/10.1158/0008-5472.Can-21-1628
Chen B, Dragomir MP, Yang C, Li Q, Horst D, Calin GA (2022) Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduct Target Ther 7(1):121. https://doi.org/10.1038/s41392-022-00975-3
Cui Y, Zhang C, Ma S, Li Z, Wang W, Li Y, Ma Y, Fang J, Wang Y, Cao W, Guan F (2021) RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma. J Exp Clin Cancer Res CR 40(1):294. https://doi.org/10.1186/s13046-021-02096-1
Dai X, Wang T, Gonzalez G, Wang Y (2018) Identification of YTH domain-containing proteins as the readers for N1-methyladenosine in RNA. Anal Chem 90(11):6380–6384. https://doi.org/10.1021/acs.analchem.8b01703
Dai X, Gonzalez G, Li L, Li J, You C, Miao W, Hu J, Fu L, Zhao Y, Li R, Li L, Chen X, Xu Y, Gu W, Wang Y (2020) YTHDF2 binds to 5-methylcytosine in RNA and modulates the maturation of ribosomal RNA. Anal Chem 92(1):1346–1354. https://doi.org/10.1021/acs.analchem.9b04505
Desrosiers R, Friderici K, Rottman F (1974) Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A 71(10):3971–3975. https://doi.org/10.1073/pnas.71.10.3971
Dixit D, Prager BC, Gimple RC, Poh HX, Wang Y, Wu Q, Qiu Z, Kidwell RL, Kim LJY, Xie Q, Vitting-Seerup K, Bhargava S, Dong Z, Jiang L, Zhu Z, Hamerlik P, Jaffrey SR, Zhao JC, Wang X, Rich JN (2021) The RNA m6A reader YTHDF2 maintains oncogene expression and is a targetable dependency in glioblastoma stem cells. Cancer Discov 11(2):480–499. https://doi.org/10.1158/2159-8290.Cd-20-0331
Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, Cesarkas K, Jacob-Hirsch J, Amariglio N, Kupiec M, Sorek R, Rechavi G (2012) Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature 485(7397):201–206. https://doi.org/10.1038/nature11112
Du H, Zhao Y, He J, Zhang Y, Xi H, Liu M, Ma J, Wu L (2016) YTHDF2 destabilizes m(6)A-containing RNA through direct recruitment of the CCR4-NOT deadenylase complex. Nat Commun 7:12626. https://doi.org/10.1038/ncomms12626
Du C, Lv C, Feng Y, Yu S (2020) Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression. J Exp Clin Cancer Res CR 39(1):223. https://doi.org/10.1186/s13046-020-01735-3
Einstein JM, Perelis M, Chaim IA, Meena JK, Nussbacher JK, Tankka AT, Yee BA, Li H, Madrigal AA, Neill NJ, Shankar A, Tyagi S, Westbrook TF, Yeo GW (2021) Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer. Mol Cell 81(15):3048-3064.e3049. https://doi.org/10.1016/j.molcel.2021.06.014
Fang R, Chen X, Zhang S, Shi H, Ye Y, Shi H, Zou Z, Li P, Guo Q, Ma L, He C, Huang S (2021) EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat Commun 12(1):177. https://doi.org/10.1038/s41467-020-20379-7
Fenger-Grøn M, Fillman C, Norrild B, Lykke-Andersen J (2005) Multiple processing body factors and the ARE binding protein TTP activate mRNA decapping. Mol Cell 20(6):905–915. https://doi.org/10.1016/j.molcel.2005.10.031
Fu Y, Zhuang X (2020) m(6)A-binding YTHDF proteins promote stress granule formation. Nat Chem Biol 16(9):955–963. https://doi.org/10.1038/s41589-020-0524-y
Gao XN, Yan F, Lin J, Gao L, Lu XL, Wei SC, Shen N, Pang JX, Ning QY, Komeno Y, Deng AL, Xu YH, Shi JL, Li YH, Zhang DE, Nervi C, Liu SJ, Yu L (2015) AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation. Leukemia 29(8):1730–1740. https://doi.org/10.1038/leu.2015.56
Gao Y, Pei G, Li D, Li R, Shao Y, Zhang QC, Li P (2019) Multivalent m(6)A motifs promote phase separation of YTHDF proteins. Cell Res 29(9):767–769. https://doi.org/10.1038/s41422-019-0210-3
Garneau NL, Wilusz J, Wilusz CJ (2007) The highways and byways of mRNA decay. Nat Rev Mol Cell Biol 8(2):113–126. https://doi.org/10.1038/nrm2104
Gatfield D, Izaurralde E (2004) Nonsense-mediated messenger RNA decay is initiated by endonucleolytic cleavage in Drosophila. Nature 429(6991):575–578. https://doi.org/10.1038/nature02559
He J, Zhou M, Yin J, Wan J, Chu J, Jia J, Sheng J, Wang C, Yin H, He F (2021) METTL3 restrains papillary thyroid cancer progression via m(6)A/c-Rel/IL-8-mediated neutrophil infiltration. Mol Ther 29(5):1821–1837. https://doi.org/10.1016/j.ymthe.2021.01.019
Hong L, Pu X, Gan H, Weng L, Zheng Q (2021) YTHDF2 inhibit the tumorigenicity of endometrial cancer via downregulating the expression of IRS1 methylated with m(6)A. J Cancer 12(13):3809–3818. https://doi.org/10.7150/jca.54527
Hou J, Zhang H, Liu J, Zhao Z, Wang J, Lu Z, Hu B, Zhou J, Zhao Z, Feng M, Zhang H, Shen B, Huang X, Sun B, Smyth MJ, He C, Xia Q (2019) YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma. Mol Cancer 18(1):163. https://doi.org/10.1186/s12943-019-1082-3
Hou G, Zhao X, Li L, Yang Q, Liu X, Huang C, Lu R, Chen R, Wang Y, Jiang B, Yu J (2021) SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs. Nucleic Acids Res 49(5):2859–2877. https://doi.org/10.1093/nar/gkab065
Hua Z, Wei R, Guo M, Lin Z, Yu X, Li X, Gu C, Yang Y (2022) YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis. Oncogene 41(10):1482–1491. https://doi.org/10.1038/s41388-022-02191-3
Jarrous N (2017) Roles of RNase P and its subunits. Trends Genetics TIG 33(9):594–603. https://doi.org/10.1016/j.tig.2017.06.006
Jin M, Li G, Liu W, Wu X, Zhu J, Zhao D, Zeng Z, Xiong M, Song Y, He X, Zhang Q, Hu K (2021) Cigarette smoking induces aberrant N(6)-methyladenosine of DAPK2 to promote non-small cell lung cancer progression by activating NF-κB pathway. Cancer Lett 518:214–229. https://doi.org/10.1016/j.canlet.2021.07.022
Ke S, Alemu EA, Mertens C, Gantman EC, Fak JJ, Mele A, Haripal B, Zucker-Scharff I, Moore MJ, Park CY, Vågbø CB, Kusśnierczyk A, Klungland A, Darnell JE Jr, Darnell RB (2015) A majority of m6A residues are in the last exons, allowing the potential for 3′UTR regulation. Genes Dev 29(19):2037–2053. https://doi.org/10.1101/gad.269415.115
Kretschmer J, Rao H, Hackert P, Sloan KE, Höbartner C, Bohnsack MT (2018) The m(6)A reader protein YTHDC2 interacts with the small ribosomal subunit and the 5’–3’ exoribonuclease XRN1. RNA (new York, NY) 24(10):1339–1350. https://doi.org/10.1261/rna.064238.117
Lau NC, Kolkman A, van Schaik FM, Mulder KW, Pijnappel WW, Heck AJ, Timmers HT (2009) Human Ccr4-not complexes contain variable deadenylase subunits. Biochem J 422(3):443–453. https://doi.org/10.1042/bj20090500
Li F, Zhao D, Wu J, Shi Y (2014) Structure of the YTH domain of human YTHDF2 in complex with an m(6)A mononucleotide reveals an aromatic cage for m(6)A recognition. Cell Res 24(12):1490–1492. https://doi.org/10.1038/cr.2014.153
Li J, Wu L, Pei M, Zhang Y (2020a) YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells. J Ovarian Res 13(1):111. https://doi.org/10.1186/s13048-020-00717-5
Li J, Xie H, Ying Y, Chen H, Yan H, He L, Xu M, Xu X, Liang Z, Liu B, Wang X, Zheng X, Xie L (2020b) YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer. Mol Cancer 19(1):152. https://doi.org/10.1186/s12943-020-01267-6
Li J, Chen Z, Chen F, Xie G, Ling Y, Peng Y, Lin Y, Luo N, Chiang CM, Wang H (2020c) Targeted mRNA demethylation using an engineered dCas13b-ALKBH5 fusion protein. Nucleic Acids Res 48(10):5684–5694. https://doi.org/10.1093/nar/gkaa269
Li H, Zhang N, Jiao X, Wang C, Sun W, He Y, Ren G, Huang S, Li M, Chang Y, Jin Z, Xie Q, Zhang X, Huang H, Jin H (2021a) Downregulation of microRNA-6125 promotes colorectal cancer growth through YTHDF2-dependent recognition of N6-methyladenosine-modified GSK3β. Clin Transl Med 11(10):e602. https://doi.org/10.1002/ctm2.602
Li Y, Sheng H, Ma F, Wu Q, Huang J, Chen Q, Sheng L, Zhu X, Zhu X, Xu M (2021b) RNA m(6)A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1/Wnt/β-catenin signaling. Cell Death Dis 12(5):479. https://doi.org/10.1038/s41419-021-03763-z
Li K, Peng ZY, Gao S, Wang QS, Wang R, Li X, Xiao GD, Zhang J, Ren H, Tang SC, Sun X (2021c) M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way. J Exp Clin Cancer Res CR 40(1):325. https://doi.org/10.1186/s13046-021-02137-9
Li DQ, Huang CC, Zhang G, Zhou LL (2021d) FTO demethylates YAP mRNA promoting oral squamous cell carcinoma tumorigenesis. Neoplasma. https://doi.org/10.4149/neo_2021_210716N967
Liu X, Yuan J, Zhang X, Li L, Dai X, Chen Q, Wang Y (2021a) ATF3 modulates the resistance of breast cancer cells to tamoxifen through an N(6)-methyladenosine-based epitranscriptomic mechanism. Chem Res Toxicol 34(7):1814–1821. https://doi.org/10.1021/acs.chemrestox.1c00206
Liu T, Wang H, Fu Z, Wang Z, Wang J, Gan X, Wang A, Wang L (2021b) Methyltransferase-like 14 suppresses growth and metastasis of renal cell carcinoma by decreasing long noncoding RNA NEAT1. Cancer Sci. https://doi.org/10.1111/cas.15212
Ma S, Yan J, Barr T, Zhang J, Chen Z, Wang LS, Sun JC, Chen J, Caligiuri MA, Yu J (2021) The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity. J Exp Med. https://doi.org/10.1084/jem.20210279
Maida Y, Yasukawa M, Furuuchi M, Lassmann T, Possemato R, Okamoto N, Kasim V, Hayashizaki Y, Hahn WC, Masutomi K (2009) An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature 461(7261):230–235. https://doi.org/10.1038/nature08283
Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR (2012) Comprehensive analysis of mRNA methylation reveals enrichment in 3’ UTRs and near stop codons. Cell 149(7):1635–1646. https://doi.org/10.1016/j.cell.2012.05.003
Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC, Shapira-Frommer R, Tawbi HA, Rubino J, Rush TS 3rd, Zhang D, Miselis NR, Samatar AA, Chun P, Rubin EH, Schiller J, Long BJ, Dayananth P, Carr D, Kirschmeier P, Bishop WR, Deng Y, Cooper A, Shipps GW, Moreno BH, Robert L, Ribas A, Flaherty KT (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight. https://doi.org/10.1172/jci.insight.92352
Paris J, Morgan M, Campos J, Spencer GJ, Shmakova A, Ivanova I, Mapperley C, Lawson H, Wotherspoon DA, Sepulveda C, Vukovic M, Allen L, Sarapuu A, Tavosanis A, Guitart AV, Villacreces A, Much C, Choe J, Azar A, van de Lagemaat LN, Vernimmen D, Nehme A, Mazurier F, Somervaille TCP, Gregory RI, O’Carroll D, Kranc KR (2019) Targeting the RNA m(6)A reader YTHDF2 selectively compromises cancer stem cells in acute myeloid leukemia. Cell Stem Cell 25(1):137-148.e136. https://doi.org/10.1016/j.stem.2019.03.021
Park OH, Ha H, Lee Y, Boo SH, Kwon DH, Song HK, Kim YK (2019) Endoribonucleolytic cleavage of m(6)A-containing RNAs by RNase P/MRP complex. Mol Cell 74(3):494-507.e498. https://doi.org/10.1016/j.molcel.2019.02.034
Patil DP, Chen CK, Pickering BF, Chow A, Jackson C, Guttman M, Jaffrey SR (2016) m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature 537(7620):369–373. https://doi.org/10.1038/nature19342
Qing Y, Dong L, Gao L, Li C, Li Y, Han L, Prince E, Tan B, Deng X, Wetzel C, Shen C, Gao M, Chen Z, Li W, Zhang B, Braas D, Ten Hoeve J, Sanchez GJ, Chen H, Chan LN, Chen CW, Ann D, Jiang L, Müschen M, Marcucci G, Plas DR, Li Z, Su R, Chen J (2021) R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m(6)A/PFKP/LDHB axis. Mol Cell 81(5):922-939.e929. https://doi.org/10.1016/j.molcel.2020.12.026
Qiu X, Yang S, Wang S, Wu J, Zheng B, Wang K, Shen S, Jeong S, Li Z, Zhu Y, Wu T, Wu X, Wu R, Liu W, Wang HY, Chen L (2021) M(6)A Demethylase ALKBH5 regulates PD-L1 expression and tumor immunoenvironment in intrahepatic cholangiocarcinoma. Cancer Res 81(18):4778–4793. https://doi.org/10.1158/0008-5472.Can-21-0468
Ries RJ, Zaccara S, Klein P, Olarerin-George A, Namkoong S, Pickering BF, Patil DP, Kwak H, Lee JH, Jaffrey SR (2019) m(6)A enhances the phase separation potential of mRNA. Nature 571(7765):424–428. https://doi.org/10.1038/s41586-019-1374-1
Roundtree IA, He C (2016) Nuclear m(6)A reader YTHDC1 regulates mRNA splicing. Trends Genetics TIG 32(6):320–321. https://doi.org/10.1016/j.tig.2016.03.006
Roundtree IA, Luo GZ, Zhang Z, Wang X, Zhou T, Cui Y, Sha J, Huang X, Guerrero L, Xie P, He E, Shen B, He C (2017) YTHDC1 mediates nuclear export of N(6)-methyladenosine methylated mRNAs. Elife. https://doi.org/10.7554/eLife.31311
Seo KW, Kleiner RE (2020) YTHDF2 recognition of N(1)-methyladenosine (m(1)A)-modified RNA is associated with transcript destabilization. ACS Chem Biol 15(1):132–139. https://doi.org/10.1021/acschembio.9b00655
Shen X, Zhao K, Xu L, Cheng G, Zhu J, Gan L, Wu Y, Zhuang Z (2020) YTHDF2 inhibits gastric cancer cell growth by regulating FOXC2 signaling pathway. Front Genet 11:592042. https://doi.org/10.3389/fgene.2020.592042
Shen J, Feng XP, Hu RB, Wang H, Wang YL, Qian JH, Zhou YX (2021) N-methyladenosine reader YTHDF2-mediated long noncoding RNA FENDRR degradation promotes cell proliferation in endometrioid endometrial carcinoma. Lab Invest 101(6):775–784. https://doi.org/10.1038/s41374-021-00543-3
Shi H, Wang X, Lu Z, Zhao BS, Ma H, Hsu PJ, Liu C, He C (2017) YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res 27(3):315–328. https://doi.org/10.1038/cr.2017.15
Song T, Yang Y, Wei H, Xie X, Lu J, Zeng Q, Peng J, Zhou Y, Jiang S, Peng J (2019) Zfp217 mediates m6A mRNA methylation to orchestrate transcriptional and post-transcriptional regulation to promote adipogenic differentiation. Nucleic Acids Res 47(12):6130–6144. https://doi.org/10.1093/nar/gkz312
Stoilov P, Rafalska I, Stamm S (2002) YTH: a new domain in nuclear proteins. Trends Biochem Sci 27(10):495–497. https://doi.org/10.1016/s0968-0004(02)02189-8
Theler D, Dominguez C, Blatter M, Boudet J, Allain FH (2014) Solution structure of the YTH domain in complex with N6-methyladenosine RNA: a reader of methylated RNA. Nucleic Acids Res 42(22):13911–13919. https://doi.org/10.1093/nar/gku1116
Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, Fu Y, Parisien M, Dai Q, Jia G, Ren B, Pan T, He C (2014) N6-methyladenosine-dependent regulation of messenger RNA stability. Nature 505(7481):117–120. https://doi.org/10.1038/nature12730
Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, Weng X, Chen K, Shi H, He C (2015) N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell 161(6):1388–1399. https://doi.org/10.1016/j.cell.2015.05.014
Wang J, Wang L, Diao J, Shi YG, Shi Y, Ma H, Shen H (2020a) Binding to m(6)A RNA promotes YTHDF2-mediated phase separation. Protein Cell 11(4):304–307. https://doi.org/10.1007/s13238-019-00660-2
Wang L, Hui H, Agrawal K, Kang Y, Li N, Tang R, Yuan J, Rana TM (2020b) m(6) A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. Embo j 39(20):e104514. https://doi.org/10.15252/embj.2020104514
Wang X, Ma R, Zhang X, Cui L, Ding Y, Shi W, Guo C, Shi Y (2021a) Crosstalk between N6-methyladenosine modification and circular RNAs: current understanding and future directions. Mol Cancer 20(1):121. https://doi.org/10.1186/s12943-021-01415-6
Wang F, Liao Y, Zhang M, Zhu Y, Wang W, Cai H, Liang J, Song F, Hou C, Huang S, Zhang Y, Wang C, Hou J (2021b) N6-methyladenosine demethyltransferase FTO-mediated autophagy in malignant development of oral squamous cell carcinoma. Oncogene 40(22):3885–3898. https://doi.org/10.1038/s41388-021-01820-7
Wang T, Liu Z, She Y, Deng J, Zhong Y, Zhao M, Li S, Xie D, Sun X, Hu X, Chen C (2021c) A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis. Cancer Lett 520:321–331. https://doi.org/10.1016/j.canlet.2021.08.007
Watatani Y, Sato Y, Miyoshi H, Sakamoto K, Nishida K, Gion Y, Nagata Y, Shiraishi Y, Chiba K, Tanaka H, Zhao L, Ochi Y, Takeuchi Y, Takeda J, Ueno H, Kogure Y, Shiozawa Y, Kakiuchi N, Yoshizato T, Nakagawa MM, Nanya Y, Yoshida K, Makishima H, Sanada M, Sakata-Yanagimoto M, Chiba S, Matsuoka R, Noguchi M, Hiramoto N, Ishikawa T, Kitagawa J, Nakamura N, Tsurumi H, Miyazaki T, Kito Y, Miyano S, Shimoda K, Takeuchi K, Ohshima K, Yoshino T, Ogawa S, Kataoka K (2019) Molecular heterogeneity in peripheral T cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia 33(12):2867–2883. https://doi.org/10.1038/s41375-019-0473-1
Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, Schulz D, Simon M, Schlegel U, Senft C, Geletneky K, Braun C, Hartung JG, Reuter D, Metz MW, Bach F, Pietsch T (2015) A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer (oxford, Engl) 51(4):522–532. https://doi.org/10.1016/j.ejca.2014.12.019
Wilson C, Chen PJ, Miao Z, Liu DR (2020) Programmable m(6)A modification of cellular RNAs with a Cas13-directed methyltransferase. Nat Biotechnol 38(12):1431–1440. https://doi.org/10.1038/s41587-020-0572-6
Wu M, Chen G, Liao X, Xiao L, Zheng J (2022) YTHDF2 interference suppresses the EMT of cervical cancer cells and enhances cisplatin chemosensitivity by regulating AXIN1. Drug Dev Res. https://doi.org/10.1002/ddr.21942
Xie H, Li J, Ying Y, Yan H, Jin K, Ma X, He L, Xu X, Liu B, Wang X, Zheng X, Xie L (2020) METTL3/YTHDF2 m(6) A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer. J Cell Mol Med 24(7):4092–4104. https://doi.org/10.1111/jcmm.15063
Xu C, Liu K, Ahmed H, Loppnau P, Schapira M, Min J (2015) Structural basis for the discriminative recognition of N6-methyladenosine RNA by the human YT521-B homology domain family of proteins. J Biol Chem 290(41):24902–24913. https://doi.org/10.1074/jbc.M115.680389
Xu J, Zheng L, Chen J, Sun Y, Lin H, Jin RA, Tang M, Liang X, Cai X (2017) Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals. Cell Death Dis 8(10):e3095. https://doi.org/10.1038/cddis.2017.411
Xu Y, Chen Y, Yao Y, Xie H, Lu G, Du C, Cheng J, Zhou J (2021a) VIRMA contributes to non-small cell lung cancer progression via N(6)-methyladenosine-dependent DAPK3 post-transcriptional modification. Cancer Lett 522:142–154. https://doi.org/10.1016/j.canlet.2021.08.027
Xu F, Li J, Ni M, Cheng J, Zhao H, Wang S, Zhou X, Wu X (2021b) FBW7 suppresses ovarian cancer development by targeting the N(6)-methyladenosine binding protein YTHDF2. Mol Cancer 20(1):45. https://doi.org/10.1186/s12943-021-01340-8
Xu P, Hu K, Zhang P, Sun ZG, Zhang N (2022) Hypoxia-mediated YTHDF2 overexpression promotes lung squamous cell carcinoma progression by activation of the mTOR/AKT axis. Cancer Cell Int 22(1):13. https://doi.org/10.1186/s12935-021-02368-y
Yamashita A, Chang TC, Yamashita Y, Zhu W, Zhong Z, Chen CY, Shyu AB (2005) Concerted action of poly(A) nucleases and decapping enzyme in mammalian mRNA turnover. Nat Struct Mol Biol 12(12):1054–1063. https://doi.org/10.1038/nsmb1016
Yang S, Wei J, Cui YH, Park G, Shah P, Deng Y, Aplin AE, Lu Z, Hwang S, He C, He YY (2019) m(6)A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun 10(1):2782. https://doi.org/10.1038/s41467-019-10669-0
Yang X, Zhang S, He C, Xue P, Zhang L, He Z, Zang L, Feng B, Sun J, Zheng M (2020) METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Mol Cancer 19(1):46. https://doi.org/10.1186/s12943-020-1146-4
Yu JH, Yang WH, Gulick T, Bloch KD, Bloch DB (2005) Ge-1 is a central component of the mammalian cytoplasmic mRNA processing body. RNA (new York, NY) 11(12):1795–1802. https://doi.org/10.1261/rna.2142405
Yuan Y, Yan G, He M, Lei H, Li L, Wang Y, He X, Li G, Wang Q, Gao Y, Qu Z, Mei Z, Shen Z, Pu J, Wang A, Zhao W, Jiang H, Du W, Yang L (2021) ALKBH5 suppresses tumor progression via an m(6)A-dependent epigenetic silencing of pre-miR-181b-1/YAP signaling axis in osteosarcoma. Cell Death Dis 12(1):60. https://doi.org/10.1038/s41419-020-03315-x
Zaccara S, Jaffrey SR (2020) A unified model for the function of YTHDF proteins in regulating m(6)A-modified mRNA. Cell 181(7):1582-1595.e1518. https://doi.org/10.1016/j.cell.2020.05.012
Zhang Z, Theler D, Kaminska KH, Hiller M, de la Grange P, Pudimat R, Rafalska I, Heinrich B, Bujnicki JM, Allain FH, Stamm S (2010) The YTH domain is a novel RNA binding domain. J Biol Chem 285(19):14701–14710. https://doi.org/10.1074/jbc.M110.104711
Zhang C, Chen Y, Sun B, Wang L, Yang Y, Ma D, Lv J, Heng J, Ding Y, Xue Y, Lu X, Xiao W, Yang YG, Liu F (2017) m(6)A modulates haematopoietic stem and progenitor cell specification. Nature 549(7671):273–276. https://doi.org/10.1038/nature23883
Zhong L, Liao D, Zhang M, Zeng C, Li X, Zhang R, Ma H, Kang T (2019) YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer Lett 442:252–261. https://doi.org/10.1016/j.canlet.2018.11.006
Zhou KI, Pan T (2018) An additional class of m(6)A readers. Nat Cell Biol 20(3):230–232. https://doi.org/10.1038/s41556-018-0046-y
Zhou J, Wan J, Gao X, Zhang X, Jaffrey SR, Qian SB (2015) Dynamic m(6)A mRNA methylation directs translational control of heat shock response. Nature 526(7574):591–594. https://doi.org/10.1038/nature15377
Zhou C, Molinie B, Daneshvar K, Pondick JV, Wang J, Van Wittenberghe N, Xing Y, Giallourakis CC, Mullen AC (2017) Genome-wide maps of m6A circRNAs identify widespread and cell-type-specific methylation patterns that are distinct from mRNAs. Cell Rep 20(9):2262–2276. https://doi.org/10.1016/j.celrep.2017.08.027
Zhou D, Tang W, Xu Y, Xu Y, Xu B, Fu S, Wang Y, Chen F, Chen Y, Han Y, Wang G (2021) METTL3/YTHDF2 m6A axis accelerates colorectal carcinogenesis through epigenetically suppressing YPEL5. Mol Oncol 15(8):2172–2184. https://doi.org/10.1002/1878-0261.12898
Zhu T, Roundtree IA, Wang P, Wang X, Wang L, Sun C, Tian Y, Li J, He C, Xu Y (2014) Crystal structure of the YTH domain of YTHDF2 reveals mechanism for recognition of N6-methyladenosine. Cell Res 24(12):1493–1496. https://doi.org/10.1038/cr.2014.152
Funding
This article is supported by the National Natural Science Foundation of China (81922003).
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. RL and YCJ drafted the manuscript. ALH and GYK edited and revised the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Liu, R., Jia, Y., Kong, G. et al. Novel insights into roles of N6-methyladenosine reader YTHDF2 in cancer progression. J Cancer Res Clin Oncol 148, 2215–2230 (2022). https://doi.org/10.1007/s00432-022-04134-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-022-04134-7